Ortin Laboratories Ltd banner
O

Ortin Laboratories Ltd
NSE:ORTINLAB

Watchlist Manager
Ortin Laboratories Ltd
NSE:ORTINLAB
Watchlist
Price: 19.63 INR
Market Cap: ₹159.6m

Relative Value

ORTINLAB doesn't have a meaningful market cap.

The Relative Value of one ORTINLAB stock under the Base Case scenario is hidden INR. Compared to the current market price of 19.63 INR, Ortin Laboratories Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ORTINLAB Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

ORTINLAB Competitors Multiples
Ortin Laboratories Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Ortin Laboratories Ltd
NSE:ORTINLAB
159.6m INR 29.3 -2.1 -2.5 -2.4
US
Eli Lilly and Co
NYSE:LLY
990.8B USD 15.2 48 32.3 34.4
US
Johnson & Johnson
NYSE:JNJ
590.6B USD 6.3 22 15.3 18.8
CH
Roche Holding AG
SIX:ROG
286.4B CHF 4.7 30.5 12.9 15
UK
AstraZeneca PLC
LSE:AZN
232.4B GBP 5.4 30.9 17 24
CH
Novartis AG
SIX:NOVN
237.5B CHF 5.4 21.8 13.5 17.3
US
Merck & Co Inc
NYSE:MRK
298.8B USD 4.6 16.3 10.2 11.9
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.4 13.3 9.7 11.4
US
Pfizer Inc
NYSE:PFE
157.2B USD 2.5 20.2 7.5 10
US
Bristol-Myers Squibb Co
NYSE:BMY
122.1B USD 2.5 17.3 6.8 8.7
P/E Multiple
Earnings Growth PEG
IN
O
Ortin Laboratories Ltd
NSE:ORTINLAB
Average P/E: 24.5
Negative Multiple: -2.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
22
7%
3.1
CH
Roche Holding AG
SIX:ROG
30.5
29%
1.1
UK
AstraZeneca PLC
LSE:AZN
30.9
26%
1.2
CH
Novartis AG
SIX:NOVN
21.8
15%
1.5
US
Merck & Co Inc
NYSE:MRK
16.3
14%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
7%
1.9
US
Pfizer Inc
NYSE:PFE
20.2
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
17.3
17%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
O
Ortin Laboratories Ltd
NSE:ORTINLAB
Average EV/EBITDA: 45.8
Negative Multiple: -2.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
32.3
18%
1.8
US
Johnson & Johnson
NYSE:JNJ
15.3
2%
7.7
CH
Roche Holding AG
SIX:ROG
12.9
5%
2.6
UK
AstraZeneca PLC
LSE:AZN
17
11%
1.5
CH
Novartis AG
SIX:NOVN
13.5
9%
1.5
US
Merck & Co Inc
NYSE:MRK
10.2
7%
1.5
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.7
7%
1.4
US
Pfizer Inc
NYSE:PFE
7.5
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
6.8
-13%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
O
Ortin Laboratories Ltd
NSE:ORTINLAB
Average EV/EBIT: 98.7
Negative Multiple: -2.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.4
17%
2
US
Johnson & Johnson
NYSE:JNJ
18.8
6%
3.1
CH
Roche Holding AG
SIX:ROG
15
6%
2.5
UK
AstraZeneca PLC
LSE:AZN
24
24%
1
CH
Novartis AG
SIX:NOVN
17.3
12%
1.4
US
Merck & Co Inc
NYSE:MRK
11.9
6%
2
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
8%
1.4
US
Pfizer Inc
NYSE:PFE
10
-1%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.7
-6%
N/A